Tracks how often Crohn's disease and ulcerative colitis occur in Seoul
Studies how often inflammatory bowel disease occurs and its course in one Seoul district.
Key facts
- Who runs it
- Asan Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- Dec 2012
- Expected to end
- Jun 2029
- Type of study
- Observational
- Record updated
- 13 January 2021
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Korean people with Crohn's disease or ulcerative colitis in a district of Seoul, to study how common these diseases are and how they progress.
- Sex
- All sexes can join.
- Disease stage
- Definite Crohn's disease or ulcerative colitis, diagnosed by set clinical, endoscopic, radiologic and biopsy criteria. For Crohn's disease, the criteria must be met for at least 2 months.
Main reasons for not taking part
- Inflammatory bowel disease that cannot be classified as Crohn's disease or ulcerative colitis
- People of ethnic groups other than Korean
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Definite cases of CD and UC; Patients are diagnosed with CD if they meet at least 2 of the following criteria:
- clinical history of abdominal pain, weight loss, malaise, diarrhea, and/or rectal bleeding
- endoscopic findings of mucosal cobblestoning, linear ulceration, skip areas, or perianal disease
- radiologic findings of stricture, fistula, mucosal cobblestoning, or ulceration
- macroscopic appearance of bowel wall induration, mesenteric lymphadenopathy, and "creeping fat" at laparotomy
- pathologic findings of transmural inflammation and/or epithelioid granulomas; Only patients who meet these criteria for at least 2 months are included; Patients are diagnosed with UC only if all 3 of the following criteria are present
- a typical history of diarrhea or blood and pus or both in the stool for longer than 4 weeks
- a typical sigmoidoscopic or colonoscopic picture with diffusely granular, friable, or ulcerated mucosa without rectal sparing or skip lesions or radiological signs of characteristic continuous granular or ulcerated mucosa
- characteristic histopathological signs of inflammation on biopsy
Who cannot take part
- IBD unclassified
- Ethnic groups other than Korean
This trial is currently available in South Korea.
- Asan Medical CenterSeoul, South KoreaContact: Suk-Kyun Yang, M.D.Taking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the incidence, prevalence, clinical characteristics and prognosis of Crohn's disease and ulcerative colitis over time in a district of Seoul, Korea.
The group in the trial
- The Songpa-Kangdong cohort of IBD
Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.
- Plain-language title
- Tracks how often Crohn's disease and ulcerative colitis occur in SeoulGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 January 2021